u/valeria_girard

Small fix — that is the New Zealand arrangement, and the question is about Australia.

Agreed that the published criteria are the authority.

Disagreeing with this bit: that advice predates the change in compounded arrangements.

Yes — and the reason to ask for the whole page is that the interesting parts are the ones people crop out to fit a screenshot.

LC-MS gives you identity; UV purity gives you a relative quantity. A document with the first and not the second, or the reverse, is answering half the question.

Did the vial lot match the paperwork lot?

How many separate lots does your series cover?

LC-MS gives you identity; UV purity gives you a relative quantity. A document with the first and not the second, or the reverse, is answering half the question.

if you are going to test, test the thing you actually received

A written baseline — dose, date, weight, waist, and how appetite feels — taken before any change is what makes the following months interpretable rather than a series of impressions.

Have now spent more on testing than on some of the orders. No regrets — the log is the reason I can buy without agonising.

Split one vial between Medutest and Janoshik. The two numbers were within half a point of each other and I stopped worrying about which lab to trust.

Do you have the trace, or only the summary?

the TGA shortage database is public and it is the source, not the news

Disagree that this is a discrepancy. 99.6% against a claimed 99.0% is inside ordinary inter-lab variance in either direction.

redact your own name, never the batch details

Related substances itemised individually is a much stronger document than a single total, because it tells you the shape of the impurity profile rather than its size.

Sent one vial to PeptideMeter and VendorInvestigate. 98.0% and a claimed 97.5%. Cost me more than the vial and I would do it again.

if you are going to test, test the thing you actually received

Are you quoting advice from before the compounded arrangements changed?

Assumed the New Zealand position applied here. It does not, and someone corrected me politely with the actual source.

the Medsafe position in New Zealand is its own thing entirely

What did the pharmacy quote for the private price?

one result is a data point, agreement between two services is evidence

Cosigning. The batch identifier is load-bearing, and a certificate that cannot be tied to the vial in your hand is not about your vial.

Right, and net peptide content is where the counterion and the water go. Both numbers can be honest and very different.

stopping is a plan, not an event

identity and quantity are two questions and most documents answer one

Are you quoting advice from before the compounded arrangements changed?

My first certificate had a compound name, a percentage and a logo. I thought that was normal. It is not, and now I know what to ask for.

What does the method line actually say? Not the technique — the column and the gradient.

A written baseline — dose, date, weight, waist, and how appetite feels — taken before any change is what makes the following months interpretable rather than a series of impressions.

Batch number and date of analysis?

the TGA shortage database is public and it is the source, not the news

Small fix — you have described interval stretching and called it a taper. The exposure profiles differ.

What are you planning to watch for, and over what period?

That is a pause rather than a stop, and the plans for the two are not the same.

UV at 214nm sees the peptide bond and picks up almost everything; at 280nm you are looking at aromatics only. Which wavelength the number came from is part of the number.

appetite comes back before the weight does

date of analysis matters as much as the number

post the claim next to the result or the number floats